In the present study, an attempt was made to develop a cyclodextrin-colchicine complex and to study its eŠect on skin permeation and deposition of colchicine. Colchicine b cyclodextrin (BCD) complex was prepared by freeze-drying method and complex formation was conˆrmed by NMR and in vitro drug release study. Formulation containing cyclodextrin-drug complex showed 6-fold increase in transdermal ‰ux in comparison with drug solution. Skin retention studies were carried out with the objective of determining the depot eŠect of elastic liposomes in skin. The amount of drug deposited was 12.4-fold higher in case of elastic liposomes of colchicine-cyclodextrin complex (567±1.5 mg) than drug solution (46±1.1 mg). The biological evaluation of various vesicular formulations and drug solution was carried out using monosodium urate-induced air pouch model. The results of anti-gout activity in rats showed better and sustained biological eŠects over 24 h measured in terms of exudate volume, reduction in leukocyte count, decrease in in‰ammatory cell accumulation, and collagen deposition with colchicine-BCD elastic liposomal formulation than drug solution. Hence the present study reveals that colchicine-cyclodextrin-elastic liposomes approach possesses good potential to enhance skin accumulation, prolong drug release, and improve the site-speciˆcity of colchicine.
INTRODUCTION
Colchicine is an ancient drug, widely used in the treatment of gout. This medication has also found a place in the treatment of several cutaneous diseases such as psoriasis 1) and actinic keratosis. 2) However, the risk/beneˆt ratio of colchicine use is high. Gastrointestinal side-eŠects such as nausea, diarrhea, vomiting, and stomach upset occur in 80％ of patients with therapeutic doses of colchicine. 3) Oral colchicine cannot be given for ＞1 week because its accumulation in the body leads to risk of bone marrow suppression. 4) Accumulation of colchicine in patients with renal dysfunction is a risk factor for neuromyopathy. 5) Colchicine can be administered intravenously; however, this route of administration is associated with potentially serious adverse eŠects such as tissue necrosis, cytopenias, disseminated intravascular coagulation, and death. 4) Another limitation of colchicine use is its very narrow therapeutic index. Colchicine is eŠective at a dose of 0.015 mg/kg, toxic in doses ＞0.1 mg/kg, and lethal when given at 0.8 mg/kg. Therefore the narrow therapeutic margin of colchicine is a source of concern for prescribing physicians. 6) Oral administration of colchicine has several dosedependent side eŠects that suggest the need for developing an alternative dosage form that selectively delivers colchicine topically to aŠected joints. Colchicine has been shown to have beneˆcial eŠects on diŠerent dermatological conditions including leukocytoclastic vasculitis, psoriasis, and Sweet's syndrome on topical administration. Topical colchicine has also been reported an eŠective treatment for actinic keratosis. The main limitation is poor skin permeation therefore eŠective concentration has not been fully developed. 7) Colchicine medication is less expensive than most available immunosuppressive agents; however, current therapy and its associated toxic eŠects limit its use asˆrst-line therapy in diŠer-ent dermatological conditions. It has been suggested that topical administration of colchicine could be beneˆcial in the treatment of gout and other dermatological conditions along with increase in its sitespeciˆcity. In our previous study, we prepared a colchicine elastic liposomal formulation and found 8-fold enhancement in skin deposition and 4-fold increase in biological anti-gout activity as evaluated by Mono sodium urate (MSU)-induced arthritis model 8) in comparison with colchicine solution in PBS. In this study an attempt was made to prepare b cyclodextrincolchicine complex and to study its eŠect on in vitro skin permeation and deposition and biological antigout activity.
Elastic liposomes have been widely studied as vehicles for dermal and transdermal drug delivery, 9) and their beneˆt in enhancing skin permeation is well established. Poor encapsulation of water-soluble drug in aqueous compartment of these vesicles, poor dermal deposition, and drug leaking of these vesicles on storage was observed. 10) Recently, encapsulation of drug in the form of cyclodextrin (CD)-drug complex in vesicular formulation has been investigated as a new strategy for overcoming the above problems and merging the relative advantages of the two types of carrier into a single system, 11) by obtaining drug-incyclodextrin-in-elastic liposome formulations. The present work was carried out to explore the advantage of using CDs as drug carriers and encapsulation of this complex in elastic vesicles and its eŠects on skin deposition of colchicine. Elastic vesicles are known to increase skin permeation of colchicine and further use of drug-BCD complex is expected to increase skin deposition due to complexation property and facilitating skin permeation due to penetration-enhancement eŠect of BCD. In particular, the focus of the present investigation was to see whether colchicine-BCD complexation would help in increasing the formation of skin depot and sustaining the release of drug.
MATERIALS AND METHODS

Materials
Colchicine was received as a gift sample from Cepham Pharmaceuticals Pvt. Ltd., India. Soya phosphatidylcholine (PC), Sephadex G-50, picrosirius red, and 6-carboxy‰uorescein (6-CF) were purchased from Sigma Chemicals USA. Span 60, bCyclodextrin, Span 80, and cholesterol were purchased from Hi Media Ltd., India. Ethanol, acetonitrile, acetic acid, hematoxylin, eosin, and phosphomolybidic acid were procured from E. Merck, India. All reagents used in this study were of analytical grade.
Preparation of Cyclodextrin-colchicine Complex
Preparation of complex of colchicine and cyclodextrin was performed by freeze-drying method. 12) Complex of colchicine and cyclodextrin (1：2 M) was made by adding a required quantity of colchicine (1 M) to aqueous cyclodextrin solution (2 M) while mixing by magnetic stirrer at slow speed (100 rpm). After 24 h agitation, the resulting solution was frozen at -60°C and lyophilized in a freeze-dryer (HETO, Allerod, Denmark) for 24 h. Formation of colchicine-cyclodextrin complex was conˆrmed by NMR studies.
Preparation of Formulations
The elastic liposomal formulation was prepared by conventional rotary evaporation sonication method. 13) Brie‰y, phospholipid and surfactant were taken in a clean, dry, round-bottom ‰ask. This lipid mixture was dissolved in chloroform : methanol mixture (2：1). The organic solvent was removed by rotary evaporation above the lipid transition temperature (Rotary Evaporator, Superˆt, India). Final traces of solvent were removed under vacuum. The deposited lipidˆlm was hydrated for 1 h with drug, drug-cyclodextrin complex, or ‰uorescence marker solution in ethanol (7％ v/v) by rotating at 60 rev min -1 at 40±1.0°C. The resulting vesicles were swollen at room temperature for 2 h to obtain large multilamellar vesicles (LMLVs). To prepare smaller vesicles, LMLVs were probe-sonicated (40 w) at 4°C for 20 min (Probe Ultrasonicator, Imeco Ultrasonics, India). The sonicated vesicles were extruded through a sandwich of 100 and 200 nm polycarbonate membranes (Millipore, USA). Theˆnal lipid and drug concentration in vesicular formulations was 5％ w/v and 0.2％ w/v, respectively.
Characterization of Elastic Liposomal Formulations
The vesicle size and distribution were determined by dynamic light scattering (DLS) method (CILAS, 1064L, France). For morphological characterization, transmission electron microscopic (TEM) studies using phosphotungastic acid as negative stain were performed (Moragagni 268D FEI, Netherlands). A drop of the sample was placed on a carboncoated copper grid to leave a thinˆlm on the grid. Before theˆlm dried on the grid, it was negatively stained with 1％ phosphotungastic acid (PTA). A drop of the staining solution was added to theˆlm and excess solution drained oŠ withˆlter paper. The grid was allowed thoroughly to dry in air and samples were viewed under a transmission electron microscope. Vesicles without sonication were also visualized by optical microscope (Olympus, DX31, Japan).
The entrapment e‹ciency was determined after separating unentrapped drug by Sephadex G-50 column. The eluted vesicles were lysed by Triton-X 100 (0.1％ v/v) and subsequently analyzed for drug content. Elastic liposomal formulation (without sonication) was diluted 5 times with 0.9％ NaCl solution and elastic liposomes/mm 3 was counted by optical microscopy using haemocytometer. Elasticity of vesicle membrane was determined by extrusion method.
Skin Permeation and Deposition Study The in vitro skin permeation of colchicine from diŠerent formulations was studied using Franz glass diŠusion cell maintained at 37±1°C under nonocclusive conditions. The eŠective permeation area of the diŠusion cell was 2.303 cm 2 . The receptor compartment contained 22.5 ml phosphate buŠer saline (PBS pH 6.4) and was constantly stirred at 100 rpm. Excised albino abdomen rat skin was mounted between the donor and the receptor compartment. Elastic liposomal formulation (2.0 ml equivalent to 4.0 mg of colchicine) was applied to the skin epidermal surface. The samples (0.5 ml) were withdrawn through the sampling port of the diŠusion cell at 1, 2, 4, 6, 12, 16, 20, and 24 h time intervals and analyzed. An equal volume of fresh phosphate buŠer maintained at 37±1°C was replaced into the receptor compartment after each sampling. An in vitro drug release study of diŠerent formulations was also performed with cellophane membrane (molecular weight cutoŠ 12000 14000, HIMEDIA, Ltd. Mumbai, India) using the same method as described above.
At the end of the permeation experiments (24 h), the surface of the skin was washed 5 times with 50％ ethanol then with water to remove excess drug from the surface. The washing protocol was veriˆed and found to remove ＞95％ of the applied dose at zero time. The skin was then cut into small pieces. The tissue was further homogenized with 50％ ethanol (10 ml) and left at room temperature for 24 h. After shaking for 5 min and centrifugation for 5 min at 3000 rpm, the colchicine content in the upper phase was determined. 14, 15) Vesicle-Skin Interaction Study Scanning Electron Microscopy Wistar rats weighing 150 200 g were divided into 4 groups each comprising 3 rats. Theˆrst group served as control and received topical application of drug solution (1.0 mg/ml) prepared in PBS pH 6.4. The second, third, and fourth groups received 1.0 ml of drug-cyclodextrin solution in PBS, colchicine elastic liposomal formulation, and colchicine-BCD elastic liposomal formulation, respectively. The formulations were applied non-occlusively to the abdomen side of the rat over an area of 1 cm 2 . The treated rats were caged and sacriˆced after 6 h of treatment. The skin was removed immediately andˆxed at 4°C in Karnovsky'ŝ xative overnight followed by 1％ w/v osmium tetraoxide for 2 h andˆnally in ruthenium tetraoxide 0.2％ w/v and K 3 Fe(CN) 6 0.25％ w/v for 1 h. After xation, the samples were dehydrated in a range of ethanolic solutions 70, 90, 95, and 100％ v/v and coated with gold coater. 16, 17) The coated samples were visualized under scanning electron microscope (SEM, LEO43 SVP, Cambridge). All investigations were performed after approval of the Institutional Animal Ethics Committee of the Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala and in accordance with the disciplinary principles and guidelines of CPCSEA.
Confocal Laser Scanning Microscopy (CLSM)
Wistar rats weighing 150 200 g were divided into 4 groups each consisting of 3 animals. First group served as control and received topical application of 1.0 ml of 0.16％ w/v solution of marker 6CF in PBS (pH 6.4). The second, third, and fourth groups received topical application of 1.0 ml of 6CF-BCD solution, 6CF loaded elastic liposomes, and 6CF-BCD loaded elastic liposomes, respectively. The formulations were applied topically on the abdomen of rats at a marked area of 1 cm 2 . The animals were caged individually after application of formulation and sacriˆced after 6 h of application. The skin was removed immediately, cut into pieces, and washed with PBS. The skin was blotted andˆxed in Carny's ‰uid (absolute alcohol : chloroform, 3：1) for 3 h and sectioned into the pieces of 1 mm 2 size and evaluated for depth of penetration of 6-CF. The full skin thickness was optically scanned at diŠerent increments through the z-axis of a CLS microscope (Leica, DMIRE2, Germany). Optical excitations were carried out with a 489 nm Argon laser beam; ‰uores-cence emission was detected above 515 nm for 6-CF.
In Vivo Evaluation
Evaluation of Anti-gout Activity To perform biological evaluation of anti-gout activity of elastic liposomal formulation of colchicine, the monosodium urate crystals were synthesized by an established procedure. 18) The crystals were suspended in PBS at a concentration of 10 mg/ml. The crystals were sonicated to obtain rod-shaped crystals of uniform length (5 25 mm) and sterilized by autoclaving at 121°C for 30 min. The subcutaneous air pouch model was used for evaluation of anti-gout activity. 19) Brie‰y, the rats were anesthetized, the dorsal area was shaved, and 10 ml sterile air was injected subcutaneously. Sterile air was reinjected in air pouch every 2 days to maintain pseudo-gout conditions. After 6 days the rats were randomly divided into 2 groups. Group 1 [GP1 (sham control)] comprised 9 animals that received 10 ml normal saline solution into subcutaneous air pouch. Group 2 (GP2) comprised 45 animals that received 10 ml MSU (1 mg/ml) into subcutaneous air pouch. Furthermore; GP2 was again subdivided into 5 subgroups each containing 9 rats. After 24 h of MSU administration, rats in theˆrst subgroup [GP2a (control group)] received no treatment whereas the second subgroup (GP2b) rats were treated with drug solution in PBS on the air pouch. Rats in the third, fourth, andˆfth subgroups were treated by applying drug-cyclodextrin solution in PBS, colchicine elastic liposomes formulation, and colchicine-cyclodextrin elastic liposomes formulation on the air pouch. Rats (n＝3) from GP1 and subgroups of GP2 were sacriˆced at 6, 12, and 24 h, respectively, by spinal dislocation method and various parameters were employed to check the extent of anti-gout activity.
Measurement of Exudate Volume of Air Pouch and Leukocytes Count
The pouch exudate was collected from all groups by glass syringe just before sacriˆcing animals. The exudate volume was measured immediately after collection by graduated centrifuge tubes. In‰ammatory exudate harvested from each animal was placed into heparinized saline. An aliquot of the diluted exudate was used to count leukocytes.
Histopathological Studies
The skin from air pouch was excised and immediately immersed in 10％ buŠered formalin, dehydrated in graded concentrations of ethanol, immersed in xylene, and embedded in para‹n. The 5-mm thick sections of skin were cut by microtome and mounted on slides using commercial Baker's mounting ‰uid. The para‹n wax was removed by warming the slide gently until the wax melted and then was washed with xylene followed by washings with absolute alcohol and water. The sections were stained with hematoxylin-eosin and picrosirius red stains to determine gross histopathology and collagen deposition, respectively. The slides were analyzed at 100-fold magniˆcation by optical microscope.
Statistical Analysis Data are expressed as mean 
RESULTS AND DISCUSSION
Colchicine is a highly hydrophilic drug and has poor skin permeation due to its hydrophilic nature. 20) Colchicine is recommended in diŠerent skin disease conditions along with primary use in gout. 1, 2) In our previous study we encapsulated colchicine in elastic liposomes and found that skin deposition was increased 10 fold in comparison with drug solution while biological activity was found to increase 4 fold. 8) In this study colchicine-b cyclodextrin complex (BCD) was encapsulated in elastic liposomes and its skin permeation and deposition potential studied. Table 1 shows the composition of diŠerent formulations of colchicine elastic liposomes and colchicine-BCD elastic liposomes. Colchicine elastic liposomal formulation was prepared using the formula PC: Span 80 (85：15) and colchicine (0.2％ w/w) as optimized in previous study. 8) BCD was selected as complexing agent among the CDs due to its low water solubility (1.88 ％ w/w) and ability to form a complex with hydrophilic drug. 21) BCD complex was reported for increasing the skin deposition of hydrophilic drug. Martins et al. 22) reported 2-fold enhancement in skin deposition of meglumine antimoniate hydrophilic drug by complexation with BCD. Colchicine is a highly hydrophilic drug and a major ratelimiting step for the transport of colchicine is its permeation through the stratum corneum (SC). 2, 23) Once permeated through the SC, colchicine is rapidly absorbed into the systemic circulation. As a result, hydrophilic drugs elicit poor local pharmacological response due to low retentivity in the skin layers. Encapsulation of colchicine in elastic liposomes was found to increase its skin deposition 8.0 fold and use of colchicine-BCD complex is further expected to increase the skin deposition of colchicine by retarding its rapid release and absorption in the systemic circulation.
In Vitro Characterizations Colchicine-BCD complex was prepared by freeze drying method. 1 H NMR spectral analysis was carried out to check the formation of colchicine-BCD complex (Fig. 1) . Triplet observed at d 7.3 and doublet at d 7.1 shows the presence of aromatic nucleus of colchicine. Doublet observed at d 4.9 accounts for BCD. Shifts in peaks at d 2.24, 2.26, and 2.6 are due to formation of complex of colchicine with BCD. 24) Formation of complex was further conˆrmed by in vitro drug release study across the cellophane membrane in comparison with plain drug. Figure 2 compares the percent drug release of colchicine from solution in PBS, colchicine-BCD complex solution in PBS, and colchicine and colchicine-BCD loaded elastic liposomal formulation across the cellophane membrane. The release rate was slower in the case of colchicine-BCD complexation in comparison with colchicine probably due to formation of complex. The release rate of colchicine from colchicine-BCD complex was lower than plain drug. After 2 h, 93.2％ drug was released from drug solution. In comparison at 2 h, 38.9％ and at 8 h 79.4％ of colchicine was released from the colchicine-BCD complex. Further decrease in release rate was observed with elastic liposomal formulation prepared with drug-BCD complex (65.9％ at 24 h and 72.7％ at 48 h). The release experiments clearly indicate sustained release of colchicine from elastic liposomal formulations. This decrease in the release rate is due to the formation of additional barrier due to complexation for releasing the drug from vesicle membrane.
DiŠerent characteristic parameters of vesicular formulations are summarized in Table 1 . Vesicle size of colchicine elastic liposome and colchicine-BCD elastic liposomes was found 135±11 and 152±14 nm, respectively. No signiˆcant diŠerence was found in no. vesicles/mm 3 of colchicine elastic liposomes and colchicine-BCD elastic liposomes formulation. The entrapment e‹ciency of colchicine elastic liposomes Vol. 130 (2010) and colchicine-BCD formulation was found 66.3± 2.2％ and 79.5±1.6％, respectively. The signiˆcantly higher entrapment e‹ciency of colchicine-BCD elastic liposomes formulation is due to better retention of colchicine-BCD complex in elastic liposomes interior due to the hydrophobic nature of BCD. Colchicine is a hydrophilic drug and has poor entrapment e‹ciency in vesicular bilayer due to poor partition. 25) Skin Permeation and Deposition Study The results of in vitro skin permeation studies of diŠerent formulations of colchicine across excised rat abdominal skin conducted using Franz-diŠusion cell are summarized in Table 2 . The value of transdermal ‰ux for colchicine and colchicine-BCD complex loaded elastic liposomes was found 44.4±1.9 and 26.4±1.2 mg/cm 2 / h, respectively. On the other hand, colchicine-BCD complex solution in PBS showed a 3.4-fold increase in skin permeation in comparison with colchicine drug solution.
Skin retention studies were carried out with the objective of determining the depot eŠect of elastic liposomes in skin. For eŠective management of in‰amma-tion in gout, and therapeutic eŠect in other dermatological conditions such as psoriasis and leukocytoclastic vasculitis, the dosage form should accumulate drug mainly into the skin. The amount of drug deposited in skin was found 8.4-fold higher after 24-h administration of elastic liposomes and 3.4-fold higher after administration of colchicine-BCD solution as compared with drug solution. Therefore it was hypothesized that encapsulation of colchicine-BCD complex in elastic liposomes could lead to potentiation of colchicine deposition. The skin deposition of colchicine-BCD formulation of elastic liposomes was found 12.4 times higher after 24-h administration ( Table 2) .
The observed better skin accumulation of colchicine-BCD elastic liposomes could be attributed to diŠerence in the rate of drug diŠusion in skin. Cyclodextrin is mainly used as permeation enhancer in pharmaceutical preparations. The feasibility of using cyclodextrin to increase the skin accumulation of colchicine was investigated. Skin permeation and deposition study showed that complexation of colchicine with cyclodextrin signiˆcantly increased its skin deposition. Colchicine is a hydrophilic drug and after reaching in deeper layers of skin, that is its site of action in diŠerent dermatological conditions, it gets rapidly absorbed in systemic circulation and shows poor local pharmacological response. 2, 23) In comparison, when encapsulated as BCD complex the drug is released slowly as evidenced by in vitro drug release study (Fig. 2) and acts as local depot. The decrease in permeation rate may be attributed to the formation of stable complex. Ammar et al. 24) reported the formation of stable b-cyclodextrin-colchicine complex with marked protection from photo-degradation of colchicine. It is reported that BCD complexation decreases the permeation of topically applied drug and increases its skin accumulation by formation of stable complex. 26) The hydrophobic nature of b-cyclodextrin retards the dissolution of water-soluble drugs to produce sustained release eŠect. 27) Results of skin permeation study also indicate the depot forming ability of colchicine-BCD formulation of elastic liposomes. The value of transdermal ‰ux for colchicine and colchicine-BCD-loaded elastic liposomal formulation was found 44.4±1.9 and 26.4±1.2 mg/cm 2 /h, respectively. The signiˆcant ( p＜0.05) decrease in ‰ux value of BCD-colchicine formulation suggests depot-forming ability of formulation. Similarly, Tenjarla et al. 28) and Simeoni et al. 29) reported reduced skin permeation and increased skin accumulation of miconazole and oxybenzone by cyclodextrin complexation.
Vesicle Skin Interaction Study The outermost layer of the skin, SC, is believed to constitute the major barrier for drug permeation and is regarded as a heterogeneous 2 compartment system composed of keratin-ˆlled corneocytes, embedded in an intercellular lipid matrix. SEM studies using rat skin were conducted to investigate the eŠect of BCD-colchicine complexation on surface morphology of skin measured in terms of lipid perturbation and pore formation on the skin surface. Figure 3(a) (d) shows SEM photomicrographs of rat skin treated with PBS (pH 6.4) containing drug considered as control, colchicines-BCD solution in PBS, and colchicine and colchicines-BCD complex-loaded elastic liposomal formulation. In rat skin incubated with PBS containing drug, there was no lipid perturbation and surface irregularities showing that drug itself does not act as permeation enhancer. In comparison in rat skin treated with colchicines-BCD complex lipid perturbation and surface disordering were observed (Fig. 3(b) ) due to penetration-enhancement eŠect of BCD. BCD has been reported to act as a skin penetration enhancer by many authors. 23 26) Skin treated with elastic liposomes encapsulated with cyclodextrin-drug complex showed the greatest surface disordering due to lipid perturbation along with pore formation (Fig. 3   (d) ). SC surface disordering is probably due to the lipid perturbation eŠect of cyclodextrin. In comparison the lipid perturbation eŠect was signiˆcantly less in skin treated with colchicine elastic liposomal formulation (Fig. 3(c) ), showing better skin permeation potential of drug-cyclodextrin elastic liposomal formulation. The observed order of disordering and pore formation of SC layer was colchicine-BCD elastic liposomes＞colchicine elastic liposomes＞col-chicine-BCD complex solution＞drug solution.
The skin deposition potential of BCD-colchicine complex was further conˆrmed by CLSM studies. Untreated rat skin did not show any ‰uorescence. Figure 4(a) (d) shows CLSm photomicrographs of rat skin treated with 6-CF solution in PBS (pH 6.4), 6CF-BCD complex solution in PBS (pH 6.4), and 6-CF and 6-CF-BCD-loaded elastic liposomal formulation. CLSM photomicrographs show signiˆcantly deeper (250 mm) and higher penetration of ‰uores-cence probe 6-CF when applied as complex encapsulated in elastic liposomal formulation (Fig. 4(d) ) in comparison with plain 6-CF-loaded elastic liposomal formulation (Fig. 4(c) ) (200 mm). Application of 6-CF-BCD complex as PBS solution (80 mm) showed 2.5-fold less skin deposition (Fig. 4(b) ) in comparison with that encapsulated in elastic liposomes. These results suggest good skin deposition potential of BCD complex-loaded elastic liposomal formulation probably due to synergistic eŠect of combination of com- 8 10,13,30,31) BCD is a well-known skin permeation enhancer and increases permeation of drug molecules by intercellular lipid perturbation as evidenced by SEM study, the same pathway that elastic liposomes follow for skin penetration. The observed better skin deposition of BCD-elastic liposmes formulation is due to the lipid perturbation eŠects of BCD that facilitated the permeation of elastic liposomes and retarded release of colchicine. Evaluation of Biological Anti-gout Activity In vivo performance of diŠerent colchicine formulations was evaluated by MSU-induced rat air pouch model. 32) Edema is a characteristic feature of in‰am-mation that was measured in terms of exudate volume in the present study. Results of exudate volume and leukocyte count are indicators of in‰ammation in joint spaces and their increase is proportional to the severity of in‰ammatory condition. The exudate collected was measured before rats were sacriˆced at 6, 12, and 24 h in various groups employed in the present study ( Table 4 ) and leukocytes quantiˆcation was done as summarized in Table 4 . There was a continuous increase in exudate volume in MSU-treated control group (GP2a; 3.0±0.2, 5.1±0.6, and 6.5± 0.9 ml measured at 6, 12, and 24 h) than saline-treated sham group (GP1; 2.0±0.1, 2.1±0.2, and 2.0± 0.2 ml). Moreover, exudate collected in the control group (GP2a) was more turbid than that from the sham control group (GP1), indicating enhanced in‰ammatory cell inˆltration. Colchicine formulations applied after 24-h administration of MSU as pseudogout conditions were fully developed at this time as evidenced by 3.0-fold higher exudate volume and leukocyte count of MSU-treated group in comparison with the sham control group. The colchicine and colchicine-BCD-complex loaded elastic liposome-treated group showed 6.6 and 8.1-fold higher reduction in exudate volume as compared with drug solution after 24 h of treatment ( Table 4) . Similar better reduction in exudates volume was also observed at 6 and 12 h of treatment. Similarly, signiˆcantly higher reduction in leucocytes count was observed after 6, 12, and 24 h of treatment with colchicine-BCD encapsulated elastic liposomal formulation in comparison with colchicineencapsulated elastic liposomes, colchicine-BCD complex solution, and drug solution in PBS groups. The better in vivo performance of BCD-colchicine complex is possibly due to increased depot-forming ability along with sustained release and increase amount of colchicine available at the site of action.
Better anti-gout activity of developed formulation was further conˆrmed by staining of air pouch membrane with eosin-hematoxylin for checking the extent of inˆltration of in‰ammatory cells and picrosirius red stain for determination of collagen deposition. 33) Figure 5 (a) (d) shows eosin-hematoxylin-stained air pouch membrane photomicrographs of colchicine solution, colchicines-BCD complex solution, colchicine, and colchicine-BCD complex-loaded elastic liposomal formulation, respectively. The level of inltrating in‰ammatory cells was minimum in colchicine-BCD elastic liposomes-treated group (Fig. 5   (d) ) whereas the maximum was in colchicine solution-treated group. The extent of treatment on air pouch membrane of diŠerent colchicine formulations was found colchicine-BCD elastic liposomes＞colchi-cines elastic liposomes＞drug-BCD complex solution ＞drug solution. In addition to this the reduction of in‰ammatory response was sustained to 24 h in colchicine-BCD elastic liposomes-treated group in comparison with the drug solution-treated group which did not show any eŠect after 6 h of administration. Figure 5 (e) (g) shows collagen-speciˆc picrosirius red stained air pouch membrane photomicrographs of saline-treated sham control group, control group, drug solution, BCD-drug complex solution, and drug and drug-BCD complex-loaded elastic liposomal formulation. Collagen deposition is also an important indicator for development ofˆbrosis associated with gout. 34) An increase in collagen deposition re‰ects the severity of disease. MSU-treated control group showed signiˆcantly higher collagen deposition in comparison with the sham control group, indicating the development of pseudo gout conditions. 8) Collagen deposition was found minimum in colchicine-BCD elastic liposomes-treated group (Fig. 5(g) ) whereas the maximum was in drug solution-treated group (Fig. 5(e) ). The extent of treatment on collagen deposition of diŠerent colchicine formulations was found drug-BCD elastic liposomes＞colchicines elastic liposomes＞drug-BCD complex solution＞ drug solution. This study further conˆrms good in vivo performance of colchicine-BCD elastic liposomal formulation and sustained and better eŠect for management of gout.
CONCLUSION
Colchicine is an ancient drug, widely used in the treatment of gout. This medication has also found a place in the treatment of several dermatological conditions due to its immunosuppressive and anti-in‰am-matory eŠects. Colchicine is a useful, inexpensive immunosuppressive agent that has application in a wide variety of dermatological diseases along with its primary use in gout. The current conventional therapy however is associated with a number of side eŠects. Drug release study in vitro shows that developed colchicine-BCD elastic liposomal formulation can sustain the release of colchicine eŠectively as compared with free drug. Skin permeation and deposition studies also have shown enhanced skin permeation and deposition of colchicine-BCD elastic liposomal formulation. Theseˆndings indicate synergistic eŠects of combination of drug in cyclodextrin in elastic liposomes. The in vivo anti-gout activity also showed better and sustained biological eŠects. Therefore the toxic side eŠects of colchicine can be expected to be reduced. We can speculate that the colchicine-BCD Vol. 130 (2010) elastic liposomes formulation is a good candidate for localized delivery of colchicine.
